General
Preferred name
RILUZOLE
Synonyms
2-Amino-6-trifluoromethoxybenzothiazole ()
Riluzole hydrochloride ()
PK 26124 ()
RP-54274 ()
Riluzole (Rilutek) ()
PK 26124 hydrochloride ()
Riluzole (PK 26124) ()
RP-54274, PK 26124 ()
Teglutik ()
Exservan ()
Tiglutik ()
NSC-753433 ()
Riluzole zentiva ()
Riluzol ()
RP 54274 ()
Rilutek ()
NSC-759823 ()
BHV-0223 ()
Tiglutik kit ()
Riluzole (hydrochloride) ()
Riluzole-13C,15N2 ()
P&D ID
PD000919
CAS
850608-87-6
1744-22-5
1215552-03-6
Tags
available
drug
Approved by
FDA
First approval
1995
Drug indication
Amyotrophic Lateral Sclerosis Treatment
Amyotrophic lateral sclerosis
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Marketed formulations may contain riluzole hydrochloride (PubChem CID 6419992). (GtoPdb)
DESCRIPTION Glutamate release inhibitor; anticonvulsant (LOPAC library)
DESCRIPTION Glutamate release inhibitor/GABA uptake inhibitor (Tocriscreen Total)
DESCRIPTION Anti-ischemic and antioxidant (Tocris Bioactive Compound Library)
DESCRIPTION Riluzole, a benzothiazole derivative with anti-excitotoxic effects, is a glutamate release inhibitor, and also induces caspase-dependent apoptosis and suppress cell proliferation in human heptocellular carcinoma. (BOC Sciences Bioactive Compounds)
Cell lines
1
Organisms
2
Compound Sets
36
AdooQ Bioactive Compound Library
A10795
BOC Sciences Bioactive Compounds
riluzole-hydrochloride-cas-850608-87-6-item-170115
Cayman Chemical Bioactives
35833
14577
25361
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL744
ChEMBL Drugs
CHEMBL744
Concise Guide to Pharmacology 2017/18
2326
Concise Guide to Pharmacology 2019/20
2326
Concise Guide to Pharmacology 2021/22
2326
Concise Guide to Pharmacology 2023/24
2326
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00740
DrugBank Approved Drugs
DB00740
DrugCentral
2382
DrugCentral Approved Drugs
2382
DrugMAP
DMECBWN
DrugMAP Approved Drugs
DMECBWN
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
2326
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL744
MedChem Express Bioactive Compound Library
HY-B0211
HY-B0211A
NCATS Inxight Approved Drugs
7LJ087RS6F
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Riluzole(Rilutek)
TargetMol Bioactive Compound Library
T0349
The Spectrum Collection
Tocris Bioactive Compound Library
0768
Tocriscreen Total
VGSC-DB
NA0059
NA0060
External IDs
59
Properties
(calculated by RDKit )
Molecular Weight
234.01
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
2
Aromatic Ring Count
2
cLogP
2.78
TPSA
48.14
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.82
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Release
MOA
Unknown molecular target
Inhibitor
Glutamate Release Inhibitors
K(V)4.3 Channel Blockers
Sodium Channel Blockers
Cystine Glutamate Transporter Inducer
glutamate inhibitor
Target
Sodium channel alpha subunit
NMDA Receptor
Sodium Channel
GABA
KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11
GABA Receptor
GluR,Sodium Channel
Pathway
Membrane Transporter/Ion Channel
Neuroscience
Neuronal Signaling
Primary Target
GABA Transporters
Member status
member
Indication
amyotrophic lateral sclerosis (ALS)
Therapeutic Class
Anticonvulsants
VGSC Target
Nav1.2
Source data